Reconstituted HDL in acute coronary syndromes

Area of Science:

• Cardiovascular Medicine
• Lipid Metabolism
• Vascular Biology

Background:

• High-density lipoprotein (HDL)-cholesterol is inversely associated with atherosclerotic cardiovascular disease.
• HDL is known to enhance cholesterol efflux and possess anti-inflammatory properties.
• Vascular function serves as a surrogate marker for atherosclerotic vascular disease.

Purpose of the Study:

• To investigate the impact of reconstituted HDL (rHDL) infusion on vascular function in patients with acute coronary syndromes (ACS).
• To assess changes in markers of inflammation and oxidative stress following rHDL infusion.
• To evaluate the clinical benefit of rapid HDL elevation in ACS patients.

Main Methods:

• Randomized, double-blind trial involving 29 ACS patients treated with rHDL or albumin.
• Forearm venous occlusion plethysmography was used to measure endothelium-dependent and -independent vasodilatation.
• Oxidized low-density lipoprotein (LDL) and high-sensitivity C-reactive protein were quantified as markers of oxidative stress and inflammation.

Main Results:

• rHDL infusion significantly increased plasma HDL and decreased LDL levels.
• No significant changes were observed in oxidized LDL or high-sensitivity C-reactive protein levels.
• Vascular function, assessed by vasodilatation responses, remained unchanged in the rHDL group compared to the albumin group.

Conclusions:

• Despite increasing HDL and reducing LDL, rHDL infusion did not improve vascular function in ACS patients.
• These findings question the clinical utility of interventions aimed at rapidly increasing HDL levels in ACS.
• The study suggests caution regarding the use of reconstituted HDL for cardiovascular benefit in this patient population.